This promising new IBD medications is showing promise in clinical trials.
Anti-TNF agents have been the dominant IBD therapy for nearly two decades; Crohn’s and ulcerative colitis patients have become familiar with common anti-TNF brand names such as Humira, Remicade, and Cimzia. These IBD medications have helped many patients with moderate to severe IBD by reducing hospitalizations, eliminating the need for surgery, and providing IBD symptom relief.
However, some patients don’t have a response—or become unresponsive over time—to anti-TNF treatments. Research teams continue to develop new medications for IBD with the aim of producing new IBD therapies with greater efficacy and fewer side effects.
Etrolizumab is one of the new IBD medications that holds promise.
What is Etrolizumab?
From pharmaceutical company Roche, etrolizumab is a monoclonal antibody that selectively targets certain integrins. As an integrin inhibitor, it is grouped into the same general category as IBD biologic agents vedolizumab and natalizumab (in addition to other drugs ending in -mab). All are monoclonal antibodies and integrin inhibitors; the difference lies in specifically which integrins they target.
What does Etrolizumab do?
Integrins are receptors located in the cell membranes, and they play a vital role in the pathology of many diseases and are involved in the processes of inflammation, wound healing, tumor formation, and more. Etrolizumab is designed to inhibit several integrins found in lymphocytes, which are involved in the immune inflammatory response.
Studies on Etrolizumab for Ulcerative Colitis
There are several Etrolizumab for Ulcerative Colitis trials taking place. One study follows 124 participants with UC found that 21% of patients taking 100mg of etrolizumab had achieved remission by week 10. In a group taking 300mg, 10% of UC patients had entered remission. In the placebo group, the remission rate was 0%.
What is Etrolizumab’s Current Status?
Etrolizumab is currently in phase III clinical trials. This means that clinical researchers and physicians are testing the drug on patients with UC to assess its efficacy, safety, and dosing. Already having shown that the drug is safe and has an effect, the ultimate goal in phase III trials is to evaluate drug’s therapeutic effect (on anywhere between 300 and 3,000 patients) before making it available on the market.
Does Etrolizumab Treat Crohn’s Disease?
Currently, Etrolizumab is also included in a clinical trial for Crohn's Disease to determine if it is safe and effective in treating moderate to severely active Crohn's Disease.
How Can I Learn More About Etrolizumab?
Learn more about Etrolizumab and check your eligibility for a Etrolizumab clinical trial near you by answering a few short questions on the Discover Therapies homepage.
Lee, H. S., Park, S.-K., & Park, D. I. (2018). Novel treatments for inflammatory bowel disease. The Korean Journal of Internal Medicine, 33(1), 20–27. http://doi.org/10.3904/kjim.2017.393
Millard, M., Odde, S., & Neamati, N. (2011). Integrin Targeted Therapeutics. Theranostics, 1, 154–188. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3086618/